Zoetis (NYSE:ZTS) Reaches New 52-Week Low – What’s Next?

Zoetis Inc. (NYSE:ZTS)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $71.00 and last traded at $72.1710, with a volume of 1329056 shares. The stock had previously closed at $73.79.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZTS. Piper Sandler decreased their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. TD Cowen lowered their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Finally, Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $109.62.

Zoetis Price Performance

The company has a market cap of $30.60 billion, a price-to-earnings ratio of 12.20, a PEG ratio of 1.28 and a beta of 0.73. The company’s 50 day moving average price is $76.01 and its 200 day moving average price is $98.13. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the business posted $1.76 earnings per share. Zoetis’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Brighton Jones LLC increased its position in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC lifted its position in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its position in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC grew its stake in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares during the period. Finally, Glenview Trust co grew its stake in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.